{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:02:46Z","timestamp":1795089766524,"version":"4.10.2"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Neuroendocrine neoplasms (NEN) encompass a diverse set of malignancies with limited precision therapy options. Recently, therapies targeting DLL3 have shown clinical efficacy in aggressive NENs, including small cell lung cancers and neuroendocrine prostate cancers. Given the continued development and expansion of DLL3-targeted therapies, we sought to characterize the expression of DLL3 and identify its clinical and molecular correlates across diverse neuroendocrine and non-neuroendocrine cancers. Here, we interrogated paired DNA and RNA-sequencing from 1,589 NENs across 29 sites, as well as 203,252 tumors across 47 cancer types. We found that high transcriptomic levels of DLL3 correlated with more aggressive histologic and mutational patterns in NENs, with adverse survival outcomes being reflected in NENs originating from the lung, pancreas, stomach, and small bowel. The heterogeneity in DLL3 expression across NENs was largely explained by site of origin, with lung, prostate, and bladder NENs exhibiting relatively high levels of DLL3, whereas gastroenteropancreatic NENs displayed relatively low expression levels. Although the therapeutic targeting of DLL3 may be less applicable for gastroenteropancreatic NENs, we did find an upregulation of alternative targets such as SEZ6, CELSR3, and SSTR2 in these settings. Lastly, expanding our investigation into non-neuroendocrine cancers, we detected an enrichment of DLL3 in both low-grade and high-grade gliomas, Merkel cell carcinomas, medulloblastomas, and melanomas, with such enrichment being associated with prolonged overall survival in gliomas, but worse overall survival in melanomas. Altogether, we demonstrate that DLL3 represents an attractive target for subsets of neuroendocrine and non-neuroendocrine cancers and uncover opportunities for future therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0501","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:30:48Z","timestamp":1738063848000},"page":"318-326","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8953-4110","authenticated-orcid":false,"given":"John R.","family":"Lozada","sequence":"first","affiliation":[{"name":"1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota."},{"name":"2Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota."},{"name":"3Medical Scientist Training Program (MD\/PhD), University of Minnesota, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8031","authenticated-orcid":false,"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[{"name":"4Caris Life Sciences, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-9843","authenticated-orcid":false,"given":"Mark G.","family":"Evans","sequence":"additional","affiliation":[{"name":"4Caris Life Sciences, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4163-8494","authenticated-orcid":false,"given":"James","family":"Wacker","sequence":"additional","affiliation":[{"name":"4Caris Life Sciences, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-5879","authenticated-orcid":false,"given":"Kathleen M.","family":"Storey","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2017-5708","authenticated-orcid":false,"given":"Emily A.","family":"Egusa","sequence":"additional","affiliation":[{"name":"3Medical Scientist Training Program (MD\/PhD), University of Minnesota, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-968X","authenticated-orcid":false,"given":"Nicholas A.","family":"Zorko","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota."},{"name":"2Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2757-5181","authenticated-orcid":false,"given":"Akhilesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9866-6657","authenticated-orcid":false,"given":"Anthony","family":"Crymes","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1381-2713","authenticated-orcid":false,"given":"Elisabeth I.","family":"Heath","sequence":"additional","affiliation":[{"name":"6Department of Oncology, Wayne State University Karmanos Cancer Institute, Detroit, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-1126","authenticated-orcid":false,"given":"Benedito A.","family":"Carneiro","sequence":"additional","affiliation":[{"name":"7Legorreta Cancer Center, Brown University, Providence, Rhode Island."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-2583","authenticated-orcid":false,"given":"Heloisa P.","family":"Soares","sequence":"additional","affiliation":[{"name":"8Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-0653","authenticated-orcid":false,"given":"Frank","family":"Cichocki","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota."},{"name":"2Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-4944","authenticated-orcid":false,"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota."},{"name":"2Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1386","authenticated-orcid":false,"given":"Emil","family":"Lou","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota."},{"name":"2Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3259-2226","authenticated-orcid":false,"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[{"name":"9Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-9655","authenticated-orcid":false,"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota."},{"name":"2Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-3557","authenticated-orcid":false,"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[{"name":"2Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1686-7103","authenticated-orcid":false,"given":"Justin H.","family":"Hwang","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota."},{"name":"2Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"2025051308565640300_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.14694\/EdBook_AM.2015.35.92","article-title":"The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap","volume":"35","author":"Klimstra","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025051308565640300_bib2","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"2025051308565640300_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41571-022-00696-0","article-title":"Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies","volume":"20","author":"Kawasaki","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025051308565640300_bib4","volume-title":"WHO classification of endocrine and neuroendocrine tumours","author":"WHO Classification of Tumours Editorial Board","year":"2022"},{"key":"2025051308565640300_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"2025051308565640300_bib6","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1038\/s41467-021-24812-3","article-title":"The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets","volume":"12","author":"van Riet","year":"2021","journal-title":"Nat Commun"},{"key":"2025051308565640300_bib7","doi-asserted-by":"crossref","first-page":"14788","DOI":"10.1073\/pnas.1410419111","article-title":"ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers","volume":"111","author":"Augustyn","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025051308565640300_bib8","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41467-022-29963-5","article-title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer","volume":"13","author":"Nouruzi","year":"2022","journal-title":"Nat Commun"},{"key":"2025051308565640300_bib9","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat Commun"},{"key":"2025051308565640300_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025051308565640300_bib11","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/cas.13997","article-title":"DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail","volume":"110","author":"Furuta","year":"2019","journal-title":"Cancer Sci"},{"key":"2025051308565640300_bib12","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025051308565640300_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025051308565640300_bib14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2020.04.017","article-title":"SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: phase 1 study","volume":"145","author":"Morgensztern","year":"2020","journal-title":"Lung Cancer"},{"key":"2025051308565640300_bib15","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-21-1533","article-title":"Radioimmunotherapy targeting delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity","volume":"28","author":"Tully","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025051308565640300_bib16","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025051308565640300_bib17","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1535-7163.MCT-23-0524","article-title":"HPN328, a trispecific T cell\u2013activating protein construct targeting DLL3-expressing solid tumors","volume":"23","author":"Molloy","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2025051308565640300_bib18","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2217\/fon-2022-0196","article-title":"Phase I trial of the DLL3\/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas","volume":"18","author":"Wermke","year":"2022","journal-title":"Future Oncol"},{"key":"2025051308565640300_bib19","doi-asserted-by":"crossref","first-page":"e166028","DOI":"10.1172\/JCI166028","article-title":"IL-18\u2013secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J Clin Invest"},{"key":"2025051308565640300_bib20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-22-2293","article-title":"Allogeneic CAR T cells targeting DLL3 are efficacious and safe in preclinical models of small cell lung cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025051308565640300_bib21","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"2025051308565640300_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"2025051308565640300_bib23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"2025051308565640300_bib24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/0008-5472.CAN-22-1433","article-title":"Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer","volume":"83","author":"Chou","year":"2023","journal-title":"Cancer Res"},{"key":"2025051308565640300_bib25","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1158\/2767-9764.CRC-24-0069","article-title":"MYBL2 drives prostate cancer plasticity: inhibiting its transcriptional target CDK2 for RB1-deficient neuroendocrine prostate cancer","volume":"4","author":"German","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"Suppl 6","key":"2025051308565640300_bib26","doi-asserted-by":"crossref","first-page":"TPS197","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS197","article-title":"Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC)","volume":"40","author":"Aggarwal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025051308565640300_bib27","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jtho.2021.07.012","article-title":"All that glitters is not gold: the story of rovalpituzumab tesirine in SCLC","volume":"16","author":"Uprety","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025051308565640300_bib28","doi-asserted-by":"crossref","first-page":"eaav0891","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025051308565640300_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12022-020-09657-8","article-title":"Diagnostic and predictive role of DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms","volume":"32","author":"Liverani","year":"2021","journal-title":"Endocr Pathol"},{"key":"2025051308565640300_bib30","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/modpathol.2010.166","article-title":"The origin of neuroendocrine tumors and the neural crest saga","volume":"24 Suppl 2","author":"Rosai","year":"2011","journal-title":"Mod Pathol"},{"key":"2025051308565640300_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.stem.2017.06.004","article-title":"ASCL1 reorganizes chromatin to direct neuronal fate and suppress tumorigenicity of glioblastoma stem cells","volume":"21","author":"Park","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2025051308565640300_bib32","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"Immunogenomic landscape of neuroendocrine prostate cancer","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025051308565640300_bib33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"2025051308565640300_bib34","doi-asserted-by":"crossref","first-page":"eade3341","DOI":"10.1126\/scitranslmed.ade3341","article-title":"Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma","volume":"15","author":"Cichocki","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025051308565640300_bib35","doi-asserted-by":"crossref","first-page":"e007340","DOI":"10.1136\/jitc-2023-007340","article-title":"Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors","volume":"12","author":"Patel","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"Suppl 16","key":"2025051308565640300_bib36","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2024.42.16_suppl.3001","article-title":"First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors","volume":"42","author":"Chandana","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"2025051308565640300_bib37","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2024.42.16_suppl.3091","article-title":"Phase Ib portion of the ACTION-1 phase Ib\/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: safety and efficacy findings","volume":"42","author":"Halperin","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025051308565640300_bib38","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1158\/2767-9764.CRC-22-0491","article-title":"The identification of CELSR3 and other potential cell surface targets in neuroendocrine prostate cancer","volume":"3","author":"Van Emmenis","year":"2023","journal-title":"Cancer Res Commun"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0501\/3537536\/crc-24-0501.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/2\/318\/3541959\/crc-24-0501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/2\/318\/3541959\/crc-24-0501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:57:06Z","timestamp":1747126626000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/2\/318\/751776\/Expression-Patterns-of-DLL3-across-Neuroendocrine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0501","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.28417573","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28417564","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28417576","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28417567","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28435508","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28417579","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28417558","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28435505","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050756","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050753","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050762","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28417570","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28435511","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28435514","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28417582","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28417561","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28435502","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050750","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28435499","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050759","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050747","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7673758","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}